I agree that this site is using cookies. You can find further informations here.
X
Rothmann, Mark
47  results:
Search for persons X
?
1

Perspectives on informative Bayesian methods in pediatrics:

Travis, James ; Rothmann, Mark ; Thomson, Andrew
Journal of Biopharmaceutical Statistics.  33 (2023)  6 - p. 830-843 , 2023
Link: https://doi.org/10.1080/..
 
?
2

14th Annual University of Pennsylvania Conference on statis..:

Imai, Kosuke ; Rosenblum, Michael ; Rothmann, Mark
Clinical Trials.  20 (2023)  4 - p. 405-415 , 2023
Link: https://doi.org/10.1177/..
 
?
3

Finding the (biomarker-defined) subgroup of patients who be..:

McShane, Lisa Meier ; Rothmann, Mark D ; Fleming, Thomas R
Clinical Trials.  20 (2023)  4 - p. 341-350 , 2023
Link: https://doi.org/10.1177/..
 
?
4

Bayesian Methods in Human Drug and Biological Products Deve..:

Ionan, Alexei C. ; Clark, Jennifer ; Travis, James...
Therapeutic Innovation & Regulatory Science.  57 (2022)  3 - p. 436-444 , 2022
Link: https://doi.org/10.1007/..
 
?
5

Should responder analyses be conducted on continuous outcom..:

Abugov, Robert ; Clark, Jennifer ; Higginbotham, Laura...
Pharmaceutical Statistics.  22 (2022)  2 - p. 312-327 , 2022
Link: https://doi.org/10.1002/..
 
?
6

Innovations in Pediatric Therapeutics Development: Principl..:

Fleming, Thomas R. ; Garnett, Christine E. ; Conklin, Laurie S....
Therapeutic Innovation & Regulatory Science.  57 (2022)  1 - p. 109-120 , 2022
Link: https://doi.org/10.1007/..
 
?
7

Retrieved-Dropout-Based multiple imputation for time-to-eve..:

He, Jiwei ; Crackel, Roberto ; Koh, William...
Journal of Biopharmaceutical Statistics.  33 (2022)  2 - p. 234-252 , 2022
Link: https://doi.org/10.1080/..
 
?
8

Statement on P-values:

Gwise, Thomas ; Rothmann, Mark D. ; James Hung, H.M....
Statistics in Biopharmaceutical Research.  13 (2021)  1 - p. 57-58 , 2021
Link: https://doi.org/10.1080/..
 
?
9

Assessing and communicating heterogeneity of treatment effe..:

Rothmann, Mark ; Crown, William ; Louis, Thomas A....
Pharmaceutical Statistics.  20 (2020)  5 - p. 952-964 , 2020
Link: https://doi.org/10.1002/..
 
?
10

Resampling‐based stepwise multiple testing procedures with ..:

He, Jiwei ; Li, Feng ; Gao, Yan.
Pharmaceutical Statistics.  20 (2020)  2 - p. 297-313 , 2020
Link: https://doi.org/10.1002/..
 
?
11

Statistical Considerations on Subgroup Analysis in Clinical..:

Alosh, Mohamed ; Fritsch, Kathleen ; Huque, Mohammad...
Statistics in Biopharmaceutical Research.  7 (2015)  4 - p. 286-303 , 2015
Link: https://doi.org/10.1080/..
 
?
12

U.S. Food and Drug Administration Approval Summary: Omaceta..:

Alvandi, Firoozeh ; Kwitkowski, Virginia E. ; Ko, Chia-Wen...
The Oncologist.  19 (2013)  1 - p. 94-99 , 2013
Link: https://doi.org/10.1634/..
 
?
13

Evaluating and Adjusting for Premature Censoring of Progres..:

Rothmann, Mark ; Koti, Kallappa ; Lee, Kyung Yul...
Journal of Biopharmaceutical Statistics.  23 (2013)  5 - p. 1091-1105 , 2013
Link: https://doi.org/10.1080/..
 
?
14

Testing in a Prespecified Subgroup and the Intent-to-Treat ..:

Rothmann, Mark D. ; Zhang, Jenny J. ; Lu, Laura.
Drug Information Journal.  46 (2012)  2 - p. 175-179 , 2012
Link: https://doi.org/10.1177/..
 
?
15

Some essential considerations in the design and conduct of ..:

Fleming, Thomas R ; Odem-Davis, Katherine ; Rothmann, Mark D.
Clinical Trials.  8 (2011)  4 - p. 432-439 , 2011
Link: https://doi.org/10.1177/..
 
1-15